UCB (OTCMKTS:UCBJF) Sees Unusually-High Trading Volume – Should You Buy?

UCB SA (OTCMKTS:UCBJF) shares saw unusually-strong trading volume on Thursday . Approximately 5,553 shares traded hands during trading, an increase of 447% from the previous session’s volume of 1,015 shares.The stock last traded at $271.71 and had previously closed at $268.39.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on UCBJF. Morgan Stanley reaffirmed an “overweight” rating on shares of UCB in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UCB in a report on Monday, October 6th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, UCB currently has a consensus rating of “Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The stock has a 50-day moving average price of $272.25 and a 200-day moving average price of $227.09.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.